Abstract: Instances of a single brain computer interface (BCI) system can be implemented on multiple devices. An active instance can control the associated device. The instances can each communicate with a neural decoding system that can receive neural signals from a user, process the neural signals, and output a command based on the processed neural signals. A device running the active instance of can be in communication with the neural decoding system to receive a command. The device can include a display, a non-transitory memory storing instructions, and a processor to execute the instructions to: run an instance of a control program; and execute the task based on the command.

Abstract: The semiconductor device package comprises a die carrier, at least one semiconductor die disposed on the carrier, the semiconductor die comprising at least one contact pad on a main face remote from the carrier, an encapsulant disposed above the semiconductor die, an electrical connector electrically connected with the contact pad, a drilling screw screwed through the encapsulant and connected with the electrical connector.

Abstract: A power relay for a vehicle is disclosed. The power relay has a housing formed by a connector base and a housing can set thereon, two connection bolts being inserted into the connector base for contacting a load circuit. The power relay further has a coil subassembly arranged in the housing and containing a solenoid coil and an armature. The armature is coupled by a force-transmission member to a contact bridge and can shift in the housing, under the effect of a magnetic field generated by the solenoid coil, in such a way that the contact bridge can be reversibly moved between a closing position, in which the contact bridge bridges the connection bolts in an electro conducting manner, and an opening position, in which the contact bridge is not in contact with the connection bolts. The housing can is configured as an injection-molded component made of plastic.

Abstract: A power relay for a vehicle, in particular a utility vehicle, is disclosed. The power relay contains a housing formed by a connecting base and a housing pot that is placed on the connecting base. Accordingly, two connecting bolts for establishing contact with an on-load circuit are formed by standard screws.

Abstract: A power relay for a vehicle, in particular a utility vehicle, is disclosed. The power relay contains a housing formed by a connecting base and a housing pot that is placed on the connecting base. Accordingly, two connecting bolts for establishing contact with an on-load circuit are formed by standard screws.

Abstract: A power relay for a vehicle is disclosed. The power relay has a housing formed by a connector base and a housing can set thereon, two connection bolts being inserted into the connector base for contacting a load circuit. The power relay further has a coil subassembly arranged in the housing and containing a solenoid coil and an armature. The armature is coupled by a force-transmission member to a contact bridge and can shift in the housing, under the effect of a magnetic field generated by the solenoid coil, in such a way that the contact bridge can be reversibly moved between a closing position, in which the contact bridge bridges the connection bolts in an electro conducting manner, and an opening position, in which the contact bridge is not in contact with the connection bolts. The housing can is configured as an injection-molded component made of plastic.

Abstract: The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

Abstract: The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

Abstract: A new approach is proposed that contemplates systems and methods to enable a user to explore his/her problems and/or linkages associated with them in a series of steps and presents a set of content (also known as a user experience) each comprising one or more content items to the user. A psycho-spiritual map is constructed for the user to explore, wherein each node in the map represents a problem, a sub-problem/factor/issue, and an emotion related to it. The map can be dynamically managed and expanded along a path of the user's exploration by a personal “agent” that understands the user's specific needs and interests. Based on such in-depth personal knowledge and understanding, the agent is capable of identifying, retrieving, customizing, and presenting a set of content to the user that specifically and continuously addresses his/her problem.

Abstract: A new approach is proposed that contemplates systems and methods to present a script of content comprising one or more content items to a user online, wherein such content is not only relevant to addressing a problem submitted by the user, but is also customized and tailored to the specific needs and preferences of the user based on the user's profile and/or emotional state at the time. Such an approach enables a personal “agent” that understands the user's emotional state, specific needs and interests by maintaining a personal profile and history of the user. Based on in-depth personal knowledge and understanding, the agent is capable of identifying, retrieving, customizing, and presenting to the user a unique experience that distinguishes it from the experiences of any other users in the general public.

Abstract: The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

Abstract: A cable sealing device (10) includes a member (14) comprising an elastomeric material and adapted to be fitted into a cable receiving aperture. The member includes a first wall (16) and a second wall (18) spaced apart from the first wall to partially define a cavity (20) between the walls. Each wall includes a cable receiving slot (e.g., 22, 24) formed in the wall. Each wall is deformable away from the respective slot to accommodate a respective cable portion (e.g., 26, 28) extended through the slot so that the wall is biased around the cable portion to minimize any opening around the cable portion passing through the slot. The slots in the respective walls cooperate to provide a redundant seal around a cable portion (30) passing through the member.

Abstract: The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and/or treatment of benign prostatic hyperplasia and/or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia/prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia/prostatic hypertrophy, as well as associated pharmaceutical compositions.

Abstract: A screw-plug terminal housing is provided having an end with four holes for receiving four connecting leads. The end has two end pieces, sections of the end pieces being angled outwardly from the housing to form a V-shaped configuration. On the inner surface of each section is provided a leaf spring, partially slit in its longitudinal direction, extending toward the interior of the housing. Inside the housing, a free end of each leaf spring clamps a connecting lead against an inside wall of the housing when a connecting lead is inserted into one of the four holes of the end. Slots in the housing allow access to the leaf spring ends to allow simple disconnection of the leads by pushing on the leaf spring to disengage the leaf spring from the lead.